Figure.

Proportional effects of persistence with statin therapy on reduction of risk for overall cancer per 10% of follow-up days covered with statins. Squares indicate adjusted hazard ratios for all covariates listed in Table 2. Horizontal lines indicate 95% confidence intervals. The 3 statin efficacy levels were created on the basis of expected amounts of low-density lipoprotein reduction from baseline.

Cases of Cancer	Hazard Ratio (95% Confidence Interval)
Women (n = 4,095)	1 (0.99–1.01)
Men (n = 4,567)	0.98 (0.97–0.99)
Age 21–49 y (n = 696)	0.99 (0.97–1.02
Age 50–65 y (n = 4,164)	0.98 (0.97–0.99)
Age ≥66 (n = 3,802)	0.98 (0.97–0.99)
Low statin efficacy (n = 3,712)	0.99 (0.98–1.01)
Medium statin efficacy (n = 4,267)	0.99 (0.98–1.01)
High statin efficacy (n = 583)	0.95 (0.92–0.97)